Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07850336 | Pancreatic Endoscopic Ultrasound-guided RadioFrequency for Inoperable Carcinoma Treatment(PERFECT) | not yet recruiting | N/A | 56 | Bojan KovacevicOTHER | 0 | Sep 30, 2026 | clinicaltrials |
| NCT07850882 | A Prospective Real-World Observational Study of Intratumoral Oncolytic Virus Injection Combined With Immune Checkpoint Inhibitors for Metastatic Tumors (Colorectal Cancer, Gastric Cancer, and Hepatocellular Carcinoma) | recruiting | — | 30 | Jie Yuan，MDOTHER | 1 | Sep 30, 2026 |
| clinicaltrials |
| NCT07850921 | REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants | not yet recruiting | Phase 1 / Phase 2 | 192 | Regeneron PharmaceuticalsINDUSTRY | 0 | Sep 30, 2026 | clinicaltrials |
| NCT00003641 | High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma | completed | Phase 3 | 1,150 | ECOG-ACRIN Cancer Research GroupNETWORK | 4 | Sep 29, 2026 | clinicaltrials |
| NCT00027326 | Collection of Blood and Urine From Patients Undergoing Radiation Therapy | enrolling by invitation | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00423644 | A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b | completed | Phase 2 | 17 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00496522 | Proton Beam Therapy for Chondrosarcoma | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00592163 | Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas | completed | Phase 1 | 20 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00924196 | Natural History Study of Patients With Neurofibromatosis Type I | active not recruiting | — | 259 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01242072 | Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies | completed | Phase 1 | 22 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01414855 | A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) | completed | Phase 2 | 100 | Genentech, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01559935 | Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma(CarBiRD) | completed | Phase 2 | 74 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01824875 | Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 144 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01896999 | Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 146 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT02345265 | Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT02446600 | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 3 | 579 | National Cancer Institute (NCI)NIH | 4 | Sep 29, 2026 | clinicaltrials |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | active not recruiting | Phase 2 | 6,452 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT02502266 | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | active not recruiting | Phase 2 / Phase 3 | 582 | National Cancer Institute (NCI)NIH | 5 | Sep 29, 2026 | clinicaltrials |
| NCT02595944 | Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)(ANVIL) | active not recruiting | Phase 3 | 903 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT02613819 | Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney(FASTRACK II) | completed | Phase 2 | 71 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03059485 | DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission | active not recruiting | Phase 2 | 82 | Beth Israel Deaconess Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03187288 | Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS | completed | Phase 1 | 13 | University Health Network, TorontoOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03391362 | Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases | active not recruiting | N/A | 100 | Brigham and Women's HospitalOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03597321 | Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML(ELIT-AML01) | active not recruiting | Phase 2 | 124 | Institut Paoli-CalmettesOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03598257 | Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer | active not recruiting | Phase 2 | 300 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT03679650 | Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients | active not recruiting | Phase 1 | 28 | Beth Israel Deaconess Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03739814 | Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT03793179 | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 600 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT03802695 | A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | recruiting | Phase 1 | 300 | Orca Biosystems, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03837899 | Durvalumab and Tremelimumab for Pediatric Malignancies | active not recruiting | Phase 1 / Phase 2 | 50 | AstraZenecaINDUSTRY | 7 | Sep 29, 2026 | clinicaltrials |
| NCT03897543 | ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 10 | Abivax S.A.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03971461 | Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma | active not recruiting | Phase 2 | 32 | NYU Langone HealthOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04085900 | Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City | recruiting | — | 40,000 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04175912 | Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04181060 | Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | recruiting | Phase 3 | 300 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04231877 | Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma | active not recruiting | Phase 1 | 56 | University of WashingtonOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04310007 | Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 117 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04402788 | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | suspended | Phase 2 / Phase 3 | 138 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04438382 | Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis | terminated | Phase 2 | 1 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04502095 | Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy | completed | Phase 4 | 89 | Roswell Park Cancer InstituteOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04548752 | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | active not recruiting | Phase 2 | 88 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04605913 | Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC | active not recruiting | Phase 1 / Phase 2 | 40 | Mayo ClinicOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04616560 | Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor | recruiting | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04628767 | Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | recruiting | Phase 2 / Phase 3 | 131 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04708418 | A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma | active not recruiting | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04751370 | Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer | active not recruiting | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04888988 | Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy(CIPN) | active not recruiting | N/A | 133 | University of Rochester NCORP Research BaseOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04890834 | Dyadic Yoga Intervention for the Improvement of Healthcare Utilization and Quality of Life in Patients With Head and Neck Cancer Undergoing Chemoradiation and Their Caregivers | active not recruiting | N/A | 415 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04981509 | Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer | recruiting | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05051722 | Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer(ECHO) | recruiting | — | 3,110 | Mayo ClinicOTHER | 1 | Sep 29, 2026 | clinicaltrials |
Data updated 35 minutes agoSource updated Sep 30, 2026source: clinicaltrials